Novetide Ltd.

Novetide specializes in Research & Development, manufacturing, and marketing of peptide based drug substances. Novetide's technology platform is based on several unique technologies, and a portfolio of know-how for the development and production of peptides through sequence assembly, down stream processing, characterization and documentation of Peptide drug substances. Our profound experience and investment in research & development generates a steady flow of products, enabling timely introduction of pharmaceutical products to market. Novetide offers a rich portfolio of proprietary custom manufactured products for clinical development and for commercial supply as well as multi-source products such as Atosiban, Bivalirudin, Degarelix, Desmopressin, Eptifibatide, Exenatide, Goserelin, Lanreotide, Leuprolide, Octreotide, Pramlintide, Teriparatide (PTH 1-34), Triptorelin Acetate, and Triptorelin Pamoate. Novetide operates two FDA inspected manufacturing facilities employed with cutting-edge technologies and state-of-the-art computerized systems to maintain its consistently high product quality, while continuously improving productivity and reliability. Production capacity through assembly and downstream processing is from gr. to hundred Kg. Novetide is committed to supporting its customers through the development pathway, regulatory support, DMF submission, IP management, and supply of large scale commercial quantities, to technology innovation, focused on added commercial value, and time to market.